Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2024 · $327,240 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $349,040 — PROJECT SUMMARY / ABSTRACT An effective HIV-1 vaccine will be one that elicits diverse anti-viral immune responses, including broadly neutralizing antibodies (bnAbs). Here, we focus on eliciting anti-CD4-binding site (CD4-BS) bnAbs, including VRC01-class bnAbs, through a guided immunization approach…
Kenneth Harold Dinnon · ROCKEFELLER UNIVERSITY · 2024 · $74,284 — PROJECT SUMMARY/ABSTRACT Alphaviruses are arthropod-transmitted viruses that cause acute febrile illness in humans, with some cases causing long-term skeletomuscular and neurological sequelae. Currently there are no FDA-approved vaccines or therapeutics for alphavirus infection, and continued globa…
BARBARA K FELBER · DIVISION OF BASIC SCIENCES - NCI · 2024 · $510,540 — We have been studying the immune response of COVID-19 cohorts longitudinally to characterize the nature and longevity of immune response (Rosati M, Am J Hematol: 97:E3, 2022; Rosati Front Immunol 12: 793953, 2021; Thomopoulos, Viruses 1:1844; 2021; Terpos, Eur J Intern Med, 89:87,2021; Pappa, Microo…
Jesus Valenzuela · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,126,987 — The accomplishment of the section are: 1. In this study, we focused on host factors that mediate Leishmania genetic exchange and explore whether host blood ingested by sand flies provides some elements absent in culture medium that promotes cell fusion and the formation of hybrid parasites. Leishma…
Lothar Hennighausen · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $242,663 — In the current reporting period, we published two COVID-19 studies, one on the impact of SARS-CoV-2 variants on alternative splicing of RNAs (PMID: 38414855) and one on computational approached to investigate variant-specific blood transcriptomes (PMID: 38307916). SARS-CoV-2 infection ranges from …
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $3,550,000 — Improvements in vaccines against influenza that increase potency, breadth and durability of protection would improve worldwide ability to combat seasonal influenza as well as emergence of new pandemic influenza viruses. Influenza vaccines have the potential to reduce the risk of symptomatic infectio…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,680,146 — Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide. Intradermal (ID) vaccination with BCG has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission. We showed that the route and dose of BCG vaccination alters circ…
Arya Biragyn · NATIONAL INSTITUTE ON AGING · 2024 · $360,948 — According to the prevailing Amyloid cascade hypothesis, Alzheimers disease (AD) is caused by decades-long deposition of neurotoxic amyloid Ab-peptide aggregates (Ab plaques) in the brain. It leads to a chain of pathological events, including tauopathy, astrogliosis, accumulation of disease associate…
PHILIP Louis FELGNER · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $1,775,381 — Project Summary/Abstract – Administrative Core We are proposing the creation of the UC Irvine Vaccines for Pandemic Preparedness Center (VPPC), a consortium that will conduct basic and translational research to develop vaccines against prototype members of the Bunyavirus, Paramyxovirus and Picornavi…
Mathias Lichterfeld · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2024 · $149,559 — Project Summary/Abstract, Immune Control (Project 4) Finding a cure for HIV-1 infection is of particular importance for the growing number of HIV-1-infected infants, children and teenagers who will have to take lifelong antiretroviral therapy if curative treatment options will not be available. Rece…
MARGIE CLAPPER · RESEARCH INST OF FOX CHASE CAN CTR · 2024 · $921,373 — Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While…
WENDELL BERES · DUKE UNIVERSITY · 2024 · $595,226 — Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV an…
Timothy R Fouts · ADVANCED BIOSCIENCE LABORATORIES, INC. · 2024 · $1,863,405 — Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV an…
AARON ESSER-KAHN · UNIVERSITY OF CHICAGO · 2024 · $1,989,733 — The offeror proposes to discover adjuvants with two sets of unique properties – (1) directing T cell fates and (2) improving the response to mRNA vaccines. This will be accomplished by screening novel immune-potentiators that direct the innate immune response of the original vaccine or adjuvant to i…
Marc Ladanyi · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $436,396 — RP3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma ABSTRACT Synovial sarcoma (SS) is driven by SS18::SSX-dependent chromatin dysregulation, suggesting that elucidating key aspects of this deregulation might point to therapeutic epigenetic vulnerabilities.…
Edward M. Schwarz · UNIVERSITY OF ROCHESTER · 2024 · $267,775 — Abstract Osteomyelitis is the bane of orthopaedic surgery, of which the majority is caused by Staphylococcus aureus. Prior to this P50 Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI), it was known that these rare infections following elective surgery (~1%), and our …
MORIYA TSUJI · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $1,089,350 — The goal of this contract project is to develop the glycolipid-based adjuvant for human use, with initial indications for a malaria vaccine. The scope of our product development project is to develop our novel CD1d-binding natural killer T (NKT) cell-stimulatory glycolipid, called 7DW8-5, as a versa…
Neil King · UNIVERSITY OF WASHINGTON · 2024 · $2,913,088 — PROJECT SUMMARY – PROJECT 5: mRNA AND mRNA-LAUNCHED NANOPARTICLE VACCINES The goal of Project 5 is to develop generalizable approaches and platforms to design, make, and evaluate mRNA-based vaccines for paramyxovirus, arenavirus, and phenuivirus antigens. We will leverage the industry experience of …
Rafi Ahmed · EMORY UNIVERSITY · 2024 · $673,340 — Our long-term goal is to understand the cellular and molecular basis of immunological memory in humans. We will address this important question in Project 1 by doing a detailed analysis of both humoral and cellular immunity in a longitudinal cohort of over > 700 COVID-19 patients that we have been f…